%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 15 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 13 0 R /GS2 14 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260320124515+00'00') /ModDate (D:20260320124515+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 11 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 5442 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces US FDA Clearance of IND)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Application for Phase 2 Study of TTK inhibitor, CFI-402257)] TJ ET BT 35.000 734.017 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 692.827 Td /F1 12.0 Tf [(New York and Hong Kong ?? November 30th, 2021 ?? Treadwell Therapeutics, a clinical stage)] TJ ET BT 35.000 678.175 Td /F1 12.0 Tf [(biotechnology company developing novel therapeutics for highly aggressive cancers, today announced)] TJ ET BT 35.000 663.523 Td /F1 12.0 Tf [(that the U.S. Food and Drug Administration \(FDA\) has approved its Investigational New Drug \(IND\))] TJ ET BT 35.000 648.871 Td /F1 12.0 Tf [(application to evaluate CFI-402257, an oral, first-in-class inhibitor of Threonine Tyrosine Kinase \(TTK,)] TJ ET BT 35.000 634.219 Td /F1 12.0 Tf [(also as MPS1\) in advanced solid tumors and breast cancer.)] TJ ET BT 35.000 607.567 Td /F1 12.0 Tf [(??TTK is a critical component of the Spindle Assembly Checkpoint and potentially represents a tumor)] TJ ET BT 35.000 592.915 Td /F1 12.0 Tf [(specific vulnerability. Pharmacologic inhibition of TTK using CFI-402257 causes tumor cells to)] TJ ET BT 35.000 578.263 Td /F1 12.0 Tf [(prematurely exit mitosis, leading to increased genomic instability and cell death,?)] TJ ET BT 471.176 578.263 Td /F1 12.0 Tf [()] TJ ET BT 474.512 578.263 Td /F1 12.0 Tf [( said Dr. Mark Bray,)] TJ ET BT 35.000 563.611 Td /F1 12.0 Tf [(Treadwell Chief Scientific Officer and Co-Founder. ??CFI-402257 was developed from concept to)] TJ ET BT 35.000 548.959 Td /F1 12.0 Tf [(clinic by our world class team. Preclinical studies and emerging clinical evidence support the use of)] TJ ET BT 35.000 534.307 Td /F1 12.0 Tf [(CFI-402257 in the context of CDK4/6 inhibitor failure in ER+/Her2- breast cancer, a segment where)] TJ ET BT 35.000 519.655 Td /F1 12.0 Tf [(there is a strong unmet need. We are excited by the promise of the molecule in advanced breast cancer)] TJ ET BT 35.000 505.003 Td /F1 12.0 Tf [(and beyond?)] TJ ET BT 111.056 505.003 Td /F1 12.0 Tf [()] TJ ET BT 114.392 505.003 Td /F1 12.0 Tf [( added Dr. Michael Tusche, Treadwell co-Chief Executive Officer.)] TJ ET BT 35.000 478.351 Td /F1 12.0 Tf [(Under this IND, Treadwell intends to initiate a Phase 2 clinical trial of CFI-402257 in the first quarter of)] TJ ET BT 35.000 463.699 Td /F1 12.0 Tf [(2022. This clinical trial is designed to confirm previously efficacious doses and to assess the safety,)] TJ ET BT 35.000 449.047 Td /F1 12.0 Tf [(tolerability, pharmacokinetics, pharmacodynamics and efficacy of CFI-402257 as a single agent in)] TJ ET BT 35.000 434.395 Td /F1 12.0 Tf [(advanced solid tumors, and in combination with fulvestrant in patients with ER+/HER2- advanced)] TJ ET BT 35.000 419.743 Td /F1 12.0 Tf [(breast cancer after disease progression on prior CDK4/6 inhibitor and endocrine therapy. Start-up)] TJ ET BT 35.000 405.091 Td /F1 12.0 Tf [(activities are currently underway.)] TJ ET BT 35.000 378.439 Td /F1 12.0 Tf [(CFI-402257 is a highly bioavailable, potent and selective inhibitor of TTK. Preclinical studies showed)] TJ ET BT 35.000 363.787 Td /F1 12.0 Tf [(robust inhibition of tumor growth in a wide variety of xenograft models. CFI-402257 also demonstrated)] TJ ET BT 35.000 349.135 Td /F1 12.0 Tf [(durable activity and a manageable safety profile as a single agent and in combination with fulvestrant in)] TJ ET BT 35.000 334.483 Td /F1 12.0 Tf [(advanced ER+ breast cancer in studies conducted at select Canadian sites.)] TJ ET BT 35.000 303.798 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 274.608 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company spun)] TJ ET BT 35.000 259.956 Td /F1 12.0 Tf [(out of the University Health Network \(UHN\) in Toronto. The company is developing first-in-class and)] TJ ET BT 35.000 245.304 Td /F1 12.0 Tf [(best-in-class medicines to address unmet needs in patients with cancer. Founded by a cadre of pre-)] TJ ET BT 35.000 230.652 Td /F1 12.0 Tf [(eminent scientific luminaries, including Dr. Tak W. Mak, the Company??s robust, internally developed)] TJ ET BT 35.000 216.000 Td /F1 12.0 Tf [(clinical pipeline includes CFI-400945 \(PLK4 inhibitor\), CFI-402257 \(TTK inhibitor\), and CFI-402411)] TJ ET BT 35.000 201.348 Td /F1 12.0 Tf [(\(HPK1 inhibitor\). Treadwell also has a robust pre-clinical pipeline with multiple biologic and next)] TJ ET BT 35.000 186.696 Td /F1 12.0 Tf [(generation TCR based cell therapy programs. For more information, please visit www.treadwelltx.com.)] TJ ET BT 35.000 156.011 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 126.821 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 124.211 m 87.020 124.211 l S 0.000 0.000 0.800 rg BT 35.000 112.169 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 109.559 m 137.192 109.559 l S q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Annot /Subtype /Link /F 28 /A 12 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 109.8379 137.1920 122.0479 ] >> endobj 12 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 14 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 15 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 17 0 R ] /Contents 16 0 R >> endobj 16 0 obj << /Length 891 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 817.558 m 129.032 817.558 l S 0.000 0.000 0.800 rg BT 35.000 805.516 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 802.906 m 149.876 802.906 l S 0.000 0.000 0.000 rg BT 35.000 778.864 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 764.212 Td /F1 12.0 Tf [(November 30, 2021)] TJ ET q 35.000 761.282 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 803.1854 149.8760 815.3954 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com) >> endobj xref 0 19 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000644 00000 n 0000006138 00000 n 0000006245 00000 n 0000006354 00000 n 0000006467 00000 n 0000006600 00000 n 0000006677 00000 n 0000006734 00000 n 0000006791 00000 n 0000006915 00000 n 0000007858 00000 n 0000007991 00000 n trailer << /Size 19 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 8070 %%EOF